...
首页> 外文期刊>OncoTargets and therapy >DUXAP8 a Pan-Cancer Prognostic Marker Involved in the Molecular Regulatory Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on Data Mining, Bioinformatics, and in vitro Validation
【24h】

DUXAP8 a Pan-Cancer Prognostic Marker Involved in the Molecular Regulatory Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on Data Mining, Bioinformatics, and in vitro Validation

机译:Duxap8涉及肝细胞癌分子调节机制的泛癌预后标志物:基于数据挖掘,生物信息学和体外验证的综合研究

获取原文

摘要

Background: Double homeobox A pseudogene 8 ( DUXAP8 ) has been identified as a key regulator at the posttranscriptional level in various types of cancers. However, whether DUXAP8 has a role in hepatocellular carcinoma (HCC) progression remains to be determined. Here, we aimed to investigate the potential clinical value of DUXAP8 as a pan-cancer marker, and its role in HCC development through an integrated analysis strategy and in vitro experimental validation. Methods: Comprehensive analysis was performed using data mined from public databases to evaluate the expression patterns and clinical value of DUXAP8 in human pan-cancers. Bioinformatics analysis was performed to investigate the potential biological functions of DUXAP8 in HCC based on TCGA database. Real-time qPCR analysis was used to examine the expression levels of DUXAP8 in HCC tissue samples and cell lines. DUXAP8 -siRNA was used to silence DUXAP8 in the Hep-G2 cell line to examine the role of DUXAP8 in HCC cell proliferation and invasion. Results: DUXAP8 was significantly upregulated in various types of human cancers and could serve as a potential pan-cancer diagnostic and prognostic biomarker. Bioinformatics analysis suggested that DUXAP8 might be involved in the regulation of the biological processes of HCC cell cycle, cell division and cell proliferation. Additionally, downregulation of DUXAP8 inhibited HCC cell proliferation and invasion in vitro. Conclusion: This study revealed that DUXAP8 may serve as a potential pan-cancer prognostic and diagnostic marker in humans. In addition, DUXAP8 promoted HCC cell proliferation and invasion, suggesting that it may represent a novel therapeutic target for HCC.
机译:背景:双homeobox a伪果蛋白8(duxap8)已被鉴定为各种类型的癌症的后颅面水平的关键调节器。但是,Duxap8是否在肝细胞癌(HCC)进展中的作用仍有待确定。在这里,我们旨在调查Duxap8作为泛癌标记的潜在临床价值,并通过综合分析策略和体外实验验证在HCC开发中的作用。方法:使用公共数据库所开采的数据进行综合分析,以评估Duxap8在人泛癌中的表达模式和临床价值。进行生物信息学分析以研究基于TCGA数据库的HCC中Duxap8的潜在生物功能。使用实时QPCR分析来检查HCC组织样本和细胞系中Duxap8的表达水平。 Duxap8 -SiRNA用于沉默于HEP-G2细胞系中的Duxap8,以检查Duxap8在HCC细胞增殖和侵袭中的作用。结果:Duxap8在各种类型的人类癌症中显着上调,可用作潜在的泛癌诊断和预后生物标志物。生物信息学分析表明Duxap8可能参与调节HCC细胞周期,细胞分裂和细胞增殖的生物过程。另外,Duxap8的下调抑制了HCC细胞增殖和体外侵袭。结论:本研究表明,Duxap8可以用作人类的潜在泛癌预后和诊断标志物。此外,Duxap8促进了HCC细胞增殖和侵袭,表明它可能代表HCC的新疗法靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号